Diane M. Bryant
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Broadcom CEO's capital warning weighs on AI chip outlook. Broadcom shares fell 4% after CEO Hock Tan issued a warning regarding capital allocation in the AI chip sector. This comment added to broader market concerns about the sustainability of high spending in the AI infrastructure space. The stock is currently trading near its 52-week low, reflecting cautious sentiment among investors despite long-term conviction from some analysts.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Keybanc cuts Jacobs Solutions price target to $166. Keybanc maintained its Overweight rating on Jacobs Solutions but lowered its price target to $166. This adjustment comes as the stock trades near the top of its 52-week range, with an average analyst target of $162.33. The company also appeared in a list of low-volatility stocks described as risky by one analyst.
Transaction History
| HAE | ▲ Buy | Grant | 2,538 | — | 7/24/2026 | View on chart |
| AVGO | ▲ Buy | Grant | 864 | $0 | 4/20/2026 | View on chart |
| J | ▲ Buy | Grant | 1,636 | $223K | 1/29/2026 | View on chart |
| HAE | ▲ Buy | Grant | 2,693 | — | 7/24/2025 | View on chart |
| AVGO | ▲ Buy | Grant | 1,602 | $0 | 4/21/2025 | View on chart |
| AVGO | ▼ Sell | Open Market | 15,000 | $3.4M | 12/23/2024 | View on chart |
| HAE | ▲ Buy | Grant | 2,207 | — | 7/25/2024 | View on chart |
| AVGO | ▲ Buy | Grant | 189 | $0 | 4/22/2024 | View on chart |
| HAE | ▲ Buy | Grant | 2,226 | — | 8/4/2023 | View on chart |
| AVGO | ▲ Buy | Grant | 397 | $0 | 4/3/2023 | View on chart |
| AVGO | ▼ Sell | Open Market | 476 | $300K | 4/5/2022 | View on chart |
| AVGO | ▲ Buy | Grant | 413 | $0 | 4/4/2022 | View on chart |
| AVGO | ▼ Sell | Open Market | 800 | $458K | 3/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump
Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.
Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.